{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:22Z","timestamp":1791665962977,"version":"4.3.4"},"reference-count":35,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"IZKF","award":["F-365"],"award-info":[{"award-number":["F-365"]}]},{"name":"IZKF","award":["Z-02\/85"],"award-info":[{"award-number":["Z-02\/85"]}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["314061271"],"award-info":[{"award-number":["314061271"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options. Theranostic approaches with adrenal specific radiotracers hold promise for improved diagnostics and treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Here, we report a new theranostic approach to advanced ACC applying (R)-1-[1-(4-[123I]iodophenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinyl amide ([123I]IMAZA) for diagnostic imaging and [131I]IMAZA for radionuclide therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sixty-nine patients with nonresectable, metastatic ACCs were screened using a diagnostic [123I]IMAZA scan. Patients with significant uptake in all tumoral lesions were offered treatment with [131I]IMAZA. Tumor response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), and adverse effects were assessed by Common Toxicity Criteria (version 5.0).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After screening, 13 patients were treated with a median of 25.7 GBq [131I]IMAZA (range 18.1-30.7 GBq). Five individuals received a second treatment course. Best response was a decrease in the RECIST target lesions of \u201326% in 2 patients. Five patients with disease stabilization experienced a median progression-free survival of 14.3 months (range 8.3-21.9). Median overall survival in all patients was 14.1 months (4.0-56.5) after therapy. Treatment was well tolerated, in other words no severe toxicities (CTCAE grade \u22653) were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with advanced ACC refractory to standard therapeutic regimens, [131I]IMAZA treatment was associated with disease stabilization and nonsignificant tumor size reduction in a significant patient fraction and only limited toxicities. High [131I]IMAZA-uptake in tumor lesions was observed in 38.5% of patients with advanced ACC, rendering [131I] IMAZA a potential treatment option in a limited, well-defined patient fraction. Further clinical trials will be necessary to evaluate the full potential of this novel theranostic approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab895","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T09:49:17Z","timestamp":1639475357000},"page":"e1348-e1355","source":"Crossref","is-referenced-by-count":14,"title":["Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma"],"prefix":"10.1210","volume":"107","author":[{"given":"Stefanie","family":"Hahner","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-9849","authenticated-orcid":false,"given":"Philipp E","family":"Hartrampf","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W","family":"Mihatsch","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Nauerz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Heinze","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"H\u00e4nscheid","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmina","family":"Teresa Fu\u00df","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-1604","authenticated-orcid":false,"given":"Christina","family":"Pamporaki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine III, University Hospital, University of Dresden, Fetscherstra\u00dfe 74, D-01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"},{"name":"Department of Internal Medicine IV, University Hospital Munich, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Ziemssenstra\u00dfe 5, D-80336 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-388X","authenticated-orcid":false,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K","family":"Buck","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schirbel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital, University of W\u00fcrzburg, Oberd\u00fcrrbacher Stra\u00dfe 6, D-97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"issue":"11","key":"2022032516110058900_CIT0001","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"ESMO guidelines committee. electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol."},{"issue":"2","key":"2022032516110058900_CIT0002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev."},{"issue":"1","key":"2022032516110058900_CIT0003","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.surg.2018.04.068","article-title":"Longitudinal patterns of recurrence in patients with adrenocortical carcinoma","volume":"165","author":"Glenn","year":"2019","journal-title":"Surgery."},{"issue":"2-03","key":"2022032516110058900_CIT0004","first-page":"109","article-title":"Advanced adrenocortical carcinoma - what to do when first-line therapy fails?","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"3","key":"2022032516110058900_CIT0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11912-019-0773-7","article-title":"Management of adrenocortical carcinoma","volume":"21","author":"Jasim","year":"2019","journal-title":"Curr Oncol Rep."},{"issue":"4","key":"2022032516110058900_CIT0006","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"23","key":"2022032516110058900_CIT0007","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med."},{"issue":"11","key":"2022032516110058900_CIT0008","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1210\/jc.2006-1007","article-title":"Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma","volume":"91","author":"Fassnacht","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022032516110058900_CIT0009","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/PPO.0b013e31829e3221","article-title":"Role of radiotherapy in adrenocortical carcinoma","volume":"19","author":"Ho","year":"2013","journal-title":"Cancer J."},{"issue":"13","key":"2022032516110058900_CIT0010","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/cncr.24331","article-title":"Radiotherapy in adrenocortical carcinoma","volume":"115","author":"Polat","year":"2009","journal-title":"Cancer."},{"issue":"5","key":"2022032516110058900_CIT0011","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijrobp.2010.04.030","article-title":"Adjuvant and definitive radiotherapy for adrenocortical carcinoma","volume":"80","author":"Sabolch","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"9","key":"2022032516110058900_CIT0012","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1210\/jc.2019-00029","article-title":"Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma","volume":"104","author":"Gharzai","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022032516110058900_CIT0013","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13014-020-01533-3","article-title":"Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis","volume":"15","author":"Zhu","year":"2020","journal-title":"Radiat Oncol."},{"issue":"3","key":"2022032516110058900_CIT0014","doi-asserted-by":"crossref","first-page":":e1-e5","DOI":"10.1210\/clinem\/dgz091","article-title":"Treatment with 90Y\/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors","volume":"105","author":"Grisanti","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2022032516110058900_CIT0015","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s00259-006-0103-9","article-title":"Imaging of adrenocortical metastases with [11C]metomidate","volume":"33","author":"Mitterhauser","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2022032516110058900_CIT0016","first-page":"275","article-title":"PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate","volume":"41","author":"Bergstr\u00f6m","year":"2000","journal-title":"J Nucl Med."},{"issue":"7","key":"2022032516110058900_CIT0017","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1210\/jc.2012-3261","article-title":"[\u00b9\u00b2\u00b3I]Iodometomidate imaging in adrenocortical carcinoma","volume":"98","author":"Kreissl","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022032516110058900_CIT0018","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1210\/jc.2008-0050","article-title":"[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes","volume":"93","author":"Hahner","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022032516110058900_CIT0019","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jc.2011-2765","article-title":"[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma","volume":"97","author":"Hahner","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2022032516110058900_CIT0020","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-021-05477-y","article-title":"Novel CYP11B-ligand [(123\/131)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience","author":"Heinze","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2022032516110058900_CIT0021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"issue":"7","key":"2022032516110058900_CIT0022","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","article-title":"EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy","volume":"35","author":"Lassmann","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022032516110058900_CIT0023","year":"2017"},{"key":"2022032516110058900_CIT0024","author":"Hahner","year":"2021"},{"issue":"3","key":"2022032516110058900_CIT0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00259-002-1025-9","article-title":"11C-metomidate PET imaging of adrenocortical cancer","volume":"30","author":"Khan","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"10","key":"2022032516110058900_CIT0026","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022032516110058900_CIT0027","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"2022032516110058900_CIT0028","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O\u2019Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022032516110058900_CIT0029","doi-asserted-by":"crossref","first-page":":1461-1468","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2022032516110058900_CIT0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer."},{"issue":"1","key":"2022032516110058900_CIT0031","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"12","key":"2022032516110058900_CIT0032","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022032516110058900_CIT0033","doi-asserted-by":"crossref","first-page":"101434","DOI":"10.1016\/j.beem.2020.101434","article-title":"Next-generation therapies for adrenocortical carcinoma","volume":"34","author":"Altieri","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"1","key":"2022032516110058900_CIT0034","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022032516110058900_CIT0035","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2018-01348","article-title":"Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication","volume":"103","author":"Lippert","year":"2018","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab895\/42106672\/dgab895.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/4\/e1348\/42994658\/dgab895.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/4\/e1348\/42994658\/dgab895.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T20:55:39Z","timestamp":1648241739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/4\/e1348\/6460696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,14]]},"published-print":{"date-parts":[[2022,3,24]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab895","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,12,14]]}}}